Research notes

The report expects 13% YoY revenue growth and margin expansion on better sales mix and cost controls, naming it a strong performer.

The report expects a 14% YoY EBITDA decline due to competition-led price erosion in Tolvaptan and gMyrbetriq, listing it as a muted performer.

The report expects 11% YoY revenue growth with gross margin expansion supporting EBITDA margin improvement.

The report expects 13% YoY revenue growth led by India chronic therapies and the Semaglutide launch, naming it among strong performers.

The report expects a 4% YoY revenue decline and a sharp EBITDA margin contraction due to absence of gRevlimid and price erosion, flagging it as a muted performer.

The report expects 18% YoY revenue growth driven by Lannett integration and Europe momentum, calling it among the strong performers this quarter.

The report expects 13% YoY revenue growth led by India formulations and Occlutech consolidation, but margins to stay under pressure from integration and higher costs.

The note states a buy call on MAHA BANK in the 83-84.5 range (CMP 83.79) with add-on-dip at 81, stop loss 79.5 and target 90 over a horizon of up to 10 days, citing a daily-chart breakout, a volume jump on intraday charts, a bullish RSI setup on the hourly chart and a higher-top higher-bottom structure.

The report projects ABREL's Q2FY27 presales to fall 83% YoY and EBITDA to remain negative at -29% margin.

The report expects Lodha's Q2FY27 revenue to grow 38% YoY and presales to rise 12% YoY, citing an impressive launch pipeline.

The report names Mahindra Lifespaces a top pick and expects Q2FY27 presales growth of 21% YoY.

The report projects Godrej Properties' Q2FY27 presales to decline 12% YoY while revenue grows 13% YoY.

The report highlights Phoenix Mills' rental-heavy portfolio providing stable, escalating rental income and expects 25% YoY EBITDA growth in Q2FY27.

The report cites Prestige among southern developers showing strong branded-end demand traction and expects new launch records in Q3FY27.

The report projects Kolte-Patil's Q2FY27 revenue to rise 165% YoY but EBITDA margin to remain negative at -5%.

The report expects Brigade's Q2FY27 presales to fall 9% YoY but highlights its rental-heavy portfolio as a cash-flow cushion.

The report lists Sobha as a top pick, expecting Q2FY27 PAT growth of 342% YoY driven by margin recovery.

The report names Oberoi Realty a top pick, citing strong NCR/branded demand, 100% launch sellout, and projects Q2FY27 presales to surge 612% YoY.

The report expects DLF's Q2FY27 revenue to decline 18% YoY and PAT to rise 24% YoY, with presales estimated to fall 71% YoY due to a high base.

The report upgrades HOMEFIRST from REDUCE to ADD with a revised RI-based target price of INR 1,250, citing improving AUM growth visibility of ~25% CAGR over FY27-FY29E, steady profitability, and favorable risk-reward after valuation de-rating from 4.0x to 2.3x 1-yr forward P/BV.

The note states a short-term 'Buy' on Sudarshan Chemical with a buying range of 1262-1275, add-on-dip at 1225, stop loss at 1199 and target of 1340 within up to 10 days, citing a bullish reversal from the 50 DEMA, a volume jump on intraday charts, a bullish RSI setup on the hourly chart and a higher-top higher-bottom hourly structure.

The report maintains a BUY rating and raises the target price from Rs 1,470 to Rs 1,650, along with upward revisions to EPS estimates of 2.2% to 12.2% across FY27-29E.

The report maintains a REDUCE rating but trims the target price slightly from Rs 3,280 to Rs 3,270, along with downward revisions to EPS estimates of about 4.5-4.9%.

The report maintains a REDUCE rating with an unchanged DCF-based target price of Rs 12,660, noting mobile segment volume weakness amid handset market softness and elevated memory prices but healthy topline growth from improved realizations.

The report maintains a REDUCE rating with an unchanged DCF-based target price of Rs 8,060 and unchanged EPS estimates, while noting expected Q2FY27 revenue growth of 31.3% YoY but a loss at the APAT level.